Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 43 - The Untold Story

Galera Posts Topline Data From Avasopasem Study In Chemoradiotherapy-Induced Esophagitis

Galera Therapeutics Inc (NASDAQ:GRTX) announced topline results from Phase 2a AESOP trial of avasopasem for severe acute radiation-induced esophagitis in lung cancer patients receiving concurrent chemoradiotherapy. Esophagitis is an early side effect of radiation or chemoradiation, causing pain, difficulties in swallowing with potential malnutrition, and dehydration. The trial enrolled 39 patients with unresectable…

Benzinga

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

Benzinga

'I was shocked when itchy skin turned out to be sign of cancer'

Lindsey Parry, a 46-year-old from Scarborough, Yorkshire, had a number of small lumps and itchy skin and thought it was just symptoms for glandular fever but it turned out to be a form of cancer

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Are XBiotech Shares Trading Higher Today

The French authority has signed off XBiotech Inc's (NASDAQ:XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study. Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic…

Benzinga

Why Are Statera Biopharma Shares Surging Today

Statera Biopharma Inc (NASDAQ:STAB) has entered into a non-binding term sheet with Immune Therapeutics Inc (OTC:IMUN) to sell its naltrexone and met-enkephalin rights. The transaction is contingent upon the negotiation of a definitive agreement and satisfaction of several closing conditions, including a contingency on Immune Therapeutics financing. Under the anticipated terms, Statera will receive an…

Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

Benzinga

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial

Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE:AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL. Sponsored by Quantum Leap, I-SPY 2.2 is an adaptive Phase 2 trial that evaluates emerging targeted agents, allowing those agents to either be combined…

Benzinga

Janey Godley smiles ahead of second last chemotherapy session

The Scots comedian was diagnosed with ovarian cancer back in December 2021.

Daily Record

Who did Malandra Burrows play in Emmerdale? Her 16-year stint as Kathy Glover as she reveals cancer diagnosis

The ex-Emmerdale star has opened up about her devastating cancer diagnosis as she prepares to embark on a gruelling chemotherapy journey

Leeds Live

Emmerdale's Malandra Burrows shares breast cancer diagnosis

The Liverpool-native is planning six months of chemotherapy treatment to battle the cancer

Liverpool Echo

Emmerdale's Malandra Burrows reveals devastating breast cancer diagnosis

Soap favourite Malandra Burrows has bravely revealed she has been diagnosed with breast cancer, and recently had an op to remove a stage three tumour, with six months of chemotherapy planned.

Daily Mirror

Woman's 'pregnancy symptoms' turned out to be deadly tumour

Doctors discovered a 'ticking time bomb' after Kirsty Axworthy pressed for answers

Wales Online

Get all your
news in one place.

100's of premium titles.
One news app.

Irish Mirror

Woman left stunned after 'pregnancy symptoms' turned out to be a deadly disease

Kirsty Axworthy was around 12 weeks pregnant when she started to experience symptoms such as high blood pressure, night sweats, exhaustion and migraines

Daily Mirror

Linda Nolan details painful chemo as she speaks of 'freedom' since cancer diagnosis

Linda Nolan has detailed the painful side effects of her chemotherapy she has to have each week because of her cancer diagnosis. She explained how she has a new perspective on life since the diagnosis

1 … 40 41 42 43

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.